Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Lumos Pharma, Inc. (NASDAQ:LUMO) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024. The company's management will present and host virtual one-on-one meetings with the investment community. The webcast will be available on the company's website, and a replay of the presentation will be accessible for 90 days. Contact Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team.

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34^th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Lumos Pharma’s management will present and host virtual one-on-one meetings with the investment community on Wednesday, February 14 during the event.

Oppenheimer 34th Annual Life Sciences Conference: February 13-14, 2024

Title:	Lumos Pharma Corporate Presentation
Date/Time:	February 14, 9:20-9:50 AM EDT
Webcast Link:	Register here

The webcast can also be found on the Company’s website under Events & Presentations in the Investors & Media section. A replay of the presentation will be available for 90 days thereafter. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team.

About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

FAQ

When is the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

The Oppenheimer 34th Annual Healthcare Life Sciences Conference is on February 13-14, 2024.

What is the ticker symbol for Lumos Pharma, Inc.?

The ticker symbol for Lumos Pharma, Inc. is LUMO.

Where can I find the webcast of Lumos Pharma's presentation?

The webcast of Lumos Pharma's presentation can be found on the company's website under Events & Presentations in the Investors & Media section.

How long will the replay of the presentation be available?

The replay of the presentation will be available for 90 days.

How can I schedule one-on-one meetings with Lumos Pharma's management team?

You can contact Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team.